Effects of a Pseudomonas aeruginosa eradication policy in a cystic fibrosis clinic

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 6, 2012, Pages 615-621

  Davidson, A George F ^a   Chilvers, Mark A ^a   Lillquist, Yolanda P ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

cystic fibrosis; economics; eradication; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; COLISTIN; PIPERACILLIN; TOBRAMYCIN;

ANTIBIOTIC THERAPY; BACTERIUM CULTURE; DRUG HYPERSENSITIVITY; EARLY INTERVENTION; ERADICATION THERAPY; HEALTH CARE POLICY; HOSPITALIZATION COST; HUMAN; LUNG CYSTIC FIBROSIS; LUNG FIBROSIS; LUNG FUNCTION; NONHUMAN; NUTRITIONAL SUPPORT; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DISEASE ERADICATION; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84867067547     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328358f5a2     Document Type: Review

References (30)

1. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis. Lancet 1985; 1:865.
2. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aerugi-nosa colonization in cystic fibrosis by early treatment. Lancet 1991; 338:725-726.
3. Stuart B, Lin J, Mogayzel PJ. Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Pediatr Respir Rev 2010; 11:177-184.
4. Ratjen F, Munck A, Kho P, Angyalosi G, the ELITE study group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65:286-291.
5. McPherson H, Rosenthal M, Bush A. Can mucoid Pseudomonas aeruginosa be eradicated in children with cystic fibrosis? Pediatr Pulmonol 2010; 45: 566-568.
6. Lee TWR. Eradication of early Pseudomonas infection in cystic fibrosis. Chronic Respir Dis 2009; 6:99-107.
7. Lillquist YP, Cho E, Davidson AGF. Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs 2009. J Cyst Fibros 2011; 10:175-180.
8. Lillquist YP, Davidson AGF, Gravelle A, et al. Pulmonary function outcome after aggressive intervention protocol for first growth Pseudomonas aerugi-nosa: 9 year experience 1995-2004. Pediatr Pulmonol 2004 (Suppl 27); abstract 295: 290.
9. Schelstraete P, Deschaght P, Van Simaey L, et al. Genotype based evaluation of Pseudomonas aeruginosa eradication treatment success in cystic fibrosis patients. J Cyst Fibros 2010; 9:99-103.
10. Mayer-Hamblett N, Kronmal RA, Gibson R, et al. Ramsey B and for the EPIC Investigators. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 2012; 47:125-134.
11. Amin R, Lam M, Dupuiis A, Ratjen F. The effect of early Pseudomonas aeruginosa treatment on lung function in paediatric cystic fibrosis. Pediatr Pulmonol 2011; 46:554-558.
12. Jouneau S, Bonizec M, Belleguic C, et al. Anti-inflammatory effect of fluvastatin on IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens in cystic fibrosis. PLoS One 2011; 6: e22655.
13. Weiss B, Bujanover Y, Yahav Y, et al. Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Pediatr Pulmonol 2010; 45:536-540.
14. Delhaes L, Monchy S, Frealle E, et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community-implications for therapeutic management. PLoS One 2012; 7:e36313.
15. Sibley CD, Surette MG. The polymicrobial nature of airway infections in cystic fibrosis: Cangene Gold Medal Lecture. Can J Microbiol 2011; 57:69-77.
16. Sibley CD, Sibley KA, Leong TA, et al. The Streptococcus milleri population of a cystic fibrosis clinic reveals patient specificity and intraspecies diversity. J Clin Microbiol 2010; 48:2592-2594.
17. Prayle A, Smyth AR. Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity. Curr Opin Pulm Med 2010; 16:604-610.
18. Scheenstra RJ, Heijerman HG, Zuur CL, et al. No hearing loss after repeated courses of tobramycin in cystic fibrosis patients. Acta Otolaryngol 2010; 130:253-258.
19. Martins LM, Camargos PA, Becker HM, et al. Hearing loss in cystic fibrosis. Int J Pediatr Otorhinolaryngol 2010; 74:469-473.
20. Florescu MC, Lyden E, Murphy PJ, et al. Long-term effect of chronic intravenous and inhaled nephrotoxic antibiotic treatment on the renal function of patients with cystic fibrosis. Hemodial Int 2012; 16:414-419.
21. Prestidge C, Chilvers MA, Davidson AG, et al. Renal function in pediatric cystic fibrosis patients in the first decade of life. Pediatr Nephrol 2011; 26:605-612.
22. Pittman JE, Calloway EH, Kiser M, et al. Age of acquisition and subsequent severity of cystic fibrosis lung disease. Pediatr Pulmonol 2011; 46:497-504.
23. Goldbeck L, Zerrer S, Schmitz TG. Monitoring quality of life in outpatients with cystic fibrosis: feasibility and longitudinal results. J Cyst Fibros 2007; 6:171-178.
24. Ullrich G, Wiedau S, Schulz W, Steinkamp G. Parental knowledge and behaviour to prevent environmental P aeruginosa acquisition in their children with CF. J Cyst Fibros 2008; 7:231-237.
25. Sansgiry SS, Joish VN, Boklage S, et al. Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Med Econ 2012; 15:219-224.
26. DeWitt EM, Grussemeyer CA, Friedman JY, et al. Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48 week multicenter clinical trial. Value Health 2012; 15:277-283.
27. Campbell M, Mahenthiralingam E, Speert D. Evaluation of random amplified polymorphic DNA typing of Pseudomonas aeruginosa. J Clin Microbiol 2000; 38:4614-4615.
28. Pressler T, Karpati F, Granstrom M, et al., Scandinavian CF Study Consortium. Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods. J Cyst Fibros 2009; 8:37-42.
29. Lee TWR, Brownlee KG, Conway SP, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003; 2:29-34.
30. Steinkamp G, Tummler B, Gappa M, et al. Long term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989; 6:91-98.